HTR3A and irritable bowel syndrome: In terms of applicability to this review, IBS-associated 5-HT dysregulation—which is implicated in altered GI motility [132, 221] and visceral hypersensitivity [143]—is already therapeutically targeted by 5-HT3R antagonists [85, 141].